[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628452":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":27,"locations":32,"responsibleParty":50,"collaborators":53,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":20,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Basic Health International, Inc.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Two-Probe Thermal Ablation Using IRIS™","EXPERIMENTAL","Participants eligible for ablation will undergo thermal ablation using the IRIS™ device with a modified two-probe protocol. The short endocervical probe will be positioned in the distal canal (just inside the cervical os) for 20 seconds at 100°C, followed by placement of the appropriate-sized flat ectocervical probe in overlapping applications of 20 seconds at 100°C until the entire squamocolumnar junction is treated.",[13],"Device: IRIS™ Thermal Ablation Device",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","IRIS™ Thermal Ablation Device","Thermal ablation will be performed using the IRIS™ device with a modified two-probe protocol. The short endocervical probe will be positioned in the distal canal for 20 seconds at 100°C, followed by overlapping applications of the appropriate-sized flat ectocervical probe for 20 seconds at 100°C until the entire squamocolumnar junction is treated.",[9],null,[22,25],{"name":23,"affiliation":5,"role":24},"Karla Alfaro, MD","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":5,"role":24},"Rachel Masch, MD",[28],{"name":23,"role":29,"phone":30,"phoneExt":20,"email":31},"CONTACT","+503 22838731","kalfaro@basichealth.org",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":20,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Basic Health International","RECRUITING","San Salvador","San Salvador Department","El Salvador","SV",{"type":41,"coordinates":42},"Point",[43,44],-89.18718,13.68935,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":30,"phoneExt":20,"email":49},"Leticia Lopez, MD","info@basichealth.org",{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Karla Alfaro","Medical Director",[54,56,59],{"name":55,"class":6},"The Cleveland Clinic",{"name":57,"class":58},"Liger Medical Llc","UNKNOWN",{"name":60,"class":6},"Medical College of Wisconsin","100628452","point-of-care---triage-and-treatment-for-cervical-pre-cancer-100628452",false,"NCT07461818","Point of Care - Triage and Treatment for Cervical Pre-cancer","POINT of CARE - Providing an Innovative New Triage and Treatment Strategy for Cervical Cancer Screening Efficiency","POC","Inclusion Criteria:\n\n* Women aged 30-49 years\n* Non-pregnant (determined by urine pregnancy test)\n* HPV-positive per Ministry of Health (MOH) records\n* Willing to undergo colposcopy and biopsies\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Plans to become pregnant during the study\n* History of LEEP or cervical ablation procedure in the past 5 years\n* History of total hysterectomy (verified by medical record or pelvic evaluation)\n* History of cervical cancer\n* Unable or unwilling to provide a permanent and reliable address\n* Unable or unwilling to provide informed consent","FEMALE","30 Years","49 Years",{"count":73,"type":74},5000,"ESTIMATED","INTERVENTIONAL",[77],"NA","This study evaluates a modified two-probe thermal ablation protocol using the IRIS™ device and retrospectively assesses an AI-based Automated Visual Evaluation (AVE) triage algorithm among HPV-positive women in El Salvador. The primary objective is to estimate 1-year cure rates of CIN2+ following treatment. A secondary objective is to evaluate the diagnostic performance of AVE compared with histopathology.",[80,81,82],"Cervical Precancer","Cervical Intraepithelial Neoplasia","Human Papillomavirus Infection",[84],"Cervical Cancer","2026-03-09",{"date":87,"type":88},"2026-03-11","ACTUAL",{"date":90,"type":74},"2026-03",{"date":92,"type":74},"2029-08",{"name":5,"class":6},1]